INTRODUCTION: The dose-volume effect of radiation therapy on breast tissue is poorly understood. We estimate NTCP parameters for breast fibrosis after external beam radiotherapy. MATERIALS AND METHODS: We pooled individual patient data of 5856 patients from 2 trials including whole breast irradiation followed with or without a boost. A two-compartment dose volume histogram model was used with boost volume as the first compartment and the remaining breast volume as second compartment. Results from START-pilot trial (n=1410) were used to test the predicted models. RESULTS: 26.8% patients in the Cambridge trial (5 years) and 20.7% patients in the EORTC trial (10 years) developed moderate-severe breast fibrosis. The best fit NTCP parameters were BEUD3(50)=136.4 Gy, γ50=0.9 and n=0.011 for the Niemierko model and BEUD3(50)=132 Gy, m=0.35 and n=0.012 for the Lyman Kutcher Burman model. The observed rates of fibrosis in the START-pilot trial agreed well with the predicted rates. CONCLUSIONS: This large multi-centre pooled study suggests that the effect of volume parameter is small and the maximum RT dose is the most important parameter to influence breast fibrosis. A small value of volume parameter 'n' does not fit with the hypothesis that breast tissue is a parallel organ. However, this may reflect limitations in our current scoring system of fibrosis.
INTRODUCTION: The dose-volume effect of radiation therapy on breast tissue is poorly understood. We estimate NTCP parameters for breast fibrosis after external beam radiotherapy. MATERIALS AND METHODS: We pooled individual patient data of 5856 patients from 2 trials including whole breast irradiation followed with or without a boost. A two-compartment dose volume histogram model was used with boost volume as the first compartment and the remaining breast volume as second compartment. Results from START-pilot trial (n=1410) were used to test the predicted models. RESULTS: 26.8% patients in the Cambridge trial (5 years) and 20.7% patients in the EORTC trial (10 years) developed moderate-severe breast fibrosis. The best fit NTCP parameters were BEUD3(50)=136.4 Gy, γ50=0.9 and n=0.011 for the Niemierko model and BEUD3(50)=132 Gy, m=0.35 and n=0.012 for the Lyman Kutcher Burman model. The observed rates of fibrosis in the START-pilot trial agreed well with the predicted rates. CONCLUSIONS: This large multi-centre pooled study suggests that the effect of volume parameter is small and the maximum RT dose is the most important parameter to influence breast fibrosis. A small value of volume parameter 'n' does not fit with the hypothesis that breast tissue is a parallel organ. However, this may reflect limitations in our current scoring system of fibrosis.
Authors: Mimi R Borrelli; Abra H Shen; Gordon K Lee; Arash Momeni; Michael T Longaker; Derrick C Wan Journal: Ann Plast Surg Date: 2019-10 Impact factor: 1.539
Authors: Tuomas Virén; Janne Heikkilä; Kimmo Myllyoja; Kristiina Koskela; Tapani Lahtinen; Jan Seppälä Journal: Radiat Oncol Date: 2015-04-08 Impact factor: 3.481
Authors: Carsten Herskind; Lin Ma; Qi Liu; Bo Zhang; Frank Schneider; Marlon R Veldwijk; Frederik Wenz Journal: Radiat Oncol Date: 2017-01-19 Impact factor: 3.481
Authors: D H M Jacobs; G Speijer; A L Petoukhova; E M A Roeloffzen; M Straver; A Marinelli; U Fisscher; A G Zwanenburg; J Merkus; C A M Marijnen; M E Mast; P C M Koper Journal: Breast Cancer Res Treat Date: 2018-02-19 Impact factor: 4.872
Authors: Emma J Harris; Mukesh B Mukesh; Ellen M Donovan; Anna M Kirby; Joanne S Haviland; Raj Jena; John Yarnold; Angela Baker; June Dean; Sally Eagle; Helen Mayles; Claire Griffin; Rosalind Perry; Andrew Poynter; Charlotte E Coles; Philip M Evans Journal: Br J Radiol Date: 2015-11-20 Impact factor: 3.039
Authors: David N Teguh; René Bol Raap; Henk Struikmans; Cees Verhoef; Linetta B Koppert; Arne Koole; Yadi Huang; Rob A van Hulst Journal: Radiat Oncol Date: 2016-09-29 Impact factor: 3.481